Literature DB >> 15521913

Point of care testing for INR monitoring: where are we now?

E T Murray1, D A Fitzmaurice, D McCahon.   

Abstract

Point of care (POC, or near patient) testing for measurement of the international normalized ratio (INR) has facilitated the devolution of service delivery from the traditional hospital outpatient setting. However it must be undertaken within the confines of safe practice involving quality control procedures. The evaluation of INR POC tests should be closely related to the clinical issues of management and, specifically, improving the quality of care. One benefit of POC testing is in the increased motivation that some practitioners feel, being able to perform diagnostic tests without sending samples to a laboratory. POC for INR testing within primary care eliminates the delay in waiting for the result to be processed by the hospital laboratory, and the subsequent delay in informing the patient of their dosing advice. This review describes the utilization of POC testing outside the laboratory setting to develop models of care for oral anticoagulation management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15521913     DOI: 10.1111/j.1365-2141.2004.05154.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  On-chip titration of an anticoagulant argatroban and determination of the clotting time within whole blood or plasma using a plug-based microfluidic system.

Authors:  Helen Song; Hung-Wing Li; Matthew S Munson; Thuong G Van Ha; Rustem F Ismagilov
Journal:  Anal Chem       Date:  2006-07-15       Impact factor: 6.986

Review 2.  The Evidence to Support Point-of-Care Testing.

Authors:  Andrew St John
Journal:  Clin Biochem Rev       Date:  2010-08

3.  Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: a meta-analysis.

Authors:  Zhe Xu; Zhiping Wang; Jingsong Ou; Yingqi Xu; Song Yang; Xi Zhang
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

4.  Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011.

Authors:  Darren M Triller; Susan Wymer; Patrick D Meek; Elaine M Hylek; Jack E Ansell
Journal:  J Community Health       Date:  2015-10

5.  Bioprosthetic vs. Mechanical Mitral Valve Replacement for Rheumatic Heart Disease in Patients Aged 50-70 Years.

Authors:  Jun Yu; Wei Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-31

6.  Correlation of point-of-care International Normalized Ratio to laboratory International Normalized Ratio in hemodialysis patients taking warfarin.

Authors:  Robert W Hoel; Robert C Albright; Lisa K Beyer; Paula J Santrach; Donna L Magtibay; Stephanie L Everson; Robert D McBane
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 8.237

7.  Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-09-01

8.  Factors determining patients' intentions to use point-of-care testing medical devices for self-monitoring: the case of international normalized ratio self-testing.

Authors:  Syed Ghulam Sarwar Shah; Julie Barnett; Jasna Kuljis; Kate Hone; Richard Kaczmarski
Journal:  Patient Prefer Adherence       Date:  2012-12-28       Impact factor: 2.711

Review 9.  Management of atrial fibrillation.

Authors:  Puneet Kakar; Christopher J Boos; Gregory Y H Lip
Journal:  Vasc Health Risk Manag       Date:  2007

10.  A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting - rationale, design and baseline characteristics.

Authors:  Caroline Laurence; Angela Gialamas; Lisa Yelland; Tanya Bubner; Philip Ryan; Kristyn Willson; Briony Glastonbury; Janice Gill; Mark Shephard; Justin Beilby
Journal:  Trials       Date:  2008-08-06       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.